Why Molecular Partners AG’s (MOLN) Stock Is Down 8.91%
As of Tuesday, November 03, Molecular Partners AG’s MOLN share price has dipped by 8.91%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Commentary & Analysis
Why Molecular Partners AG’s (MOLN) Stock Is Down 5.03%
As of Monday, November 02, Molecular Partners AG’s MOLN share price has dipped by 5.03%, which has investors questioning if this is right time to buy.Michael Rose
Why Molecular Partners AG’s (MOLN) Stock Is Up 5.34%
As of Monday, October 19, Molecular Partners AG’s MOLN share price has surged by 5.34%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Molecular Partners AG’s (MOLN) Stock Is Down 5.19%
As of Monday, October 12, Molecular Partners AG’s MOLN share price has dipped by 5.19%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Molecular Partners AG’s (MOLN) Stock Is Down 5.23%
As of Monday, September 21, Molecular Partners AG’s MOLN share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $121.9 | $227.3 | 24% |
|
| Shares Out (Mil) | 47.4 | 53.4 | 46% |
|
| Institutional Ownership | 67.5% | 92.9% | 42% |
|
| Float (Mil) | 20.7 | 41.4 | 29% |
|
| Beta | na | 0.95 | na |
|
| Avg Daily Volume (000s) | 2 | 468 | 10% |
|
| Price Change (52-week) |
(11.5%) | 47.4% | 39% |
|
| Growth | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (1.8%) | (10.1%) | 37% |
|
| EPS (5yr) | 6.0% | 15.8% | 40 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (26.4%) | (15.7%) | 24% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 3 | 3 | |
| Current EPS | ($0.441) | ($1.359) | ($0.130) | |
| Month Ago EPS | ($0.269) | ($0.798) | $0.283 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.441) | ($0.798) | $0.283 | |
| Year/Year Chg | 0.7% | (34.9%) | (37.2%) | |
| Financials | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($63) | ($44) | 14% |
|
| EPS (TTM) | ($1.682) | ($1.600) | 17% |
|
| Operating Cash Flow (TTM) (Mil) | ($57) | ($34) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($18) | $1 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $2 | $4 | 21% |
|
| Enterprise Value (Q1) (Mil) | $52 | $174 | 16% |
|
| Valuation | MOLN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.72 | 2.14 | 48% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | MOLN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.5% | na |
|
| Net Margin | na | (69.8%) | na |
|
| ROA | (50.7%) | (47.1%) | 11% |
|
| ROE | (61.3%) | (52.0%) | 13% |
|
| Liabilities to Assets | 22.7% | 29.7% | 15% |
|
| F-Score | 1 | 2 | 1% |
|
Molecular Partners AG did not pass any screens on 11/4/2026.
